Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease

Journal of Gastroenterology

Volumn 33, Issue 4, 1998, Pages 571-574

  Kotanagi, Hitoshi ^a   Ito, Masanao ^a   Koyama, Kenji ^a   Chiba, Mitsuro ^a  

^a AKITA UNIVERSITY   (Japan)

Author keywords

5 aminosalicylic acid (5 ASA); Crohn's disease; Pancytopenia

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CASE REPORT; CROHN DISEASE; DIARRHEA; DRUG USE; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEVER; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MALAISE; MALE; NAUSEA; PANCYTOPENIA; PATIENT MONITORING; PRIORITY JOURNAL; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MESALAMINE; PANCYTOPENIA; TIME FACTORS;

EID: 0031848690     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350050135     Document Type: Article

References (34)

1. Azad-Kahn AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;II:892-895.
2. van Hees PAM, Bakker JH, van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine. Gut 1980;21:632-635.
3. Klotz U, Marier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980;303:1499-1502.
4. Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. BMJ 1982;287:23-24.
5. Brimblecombe R. Mesalazine: A global safety evaluation. Scand J Gastroenterol 1990:25(Suppl 172):66-68.
6. Campieri M, Lanfranchi GA, Brignola C, et al. 5-Aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine. Lancet 1984;I:403.
7. Sandberg-Gerten H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis: A study of tolerance and relapse-prevention properties. Gastroenterology 1986;90:1024-1030.
8. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol 1987;22:332-336.
9. Turunen U, Elomaa I, Anttila VJ, et al. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scand J Gastroenterol 1987;22:798-802.
10. Habel FM, Greenberg GR. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Am J Gastroenterol 1988;83:15-19.
11. Wyatt S, Joyner MV, Daneshmend TK, Filgrastrim for mesalazine-associated neutropenia. Lancet 1993;341:1476.
12. Casellas F, Vallano A, Malagelada JR. Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories. J Clin Gastroenterol 1996;2:160-161.
13. Abboudi ZH, Marsh JCW, Smith-Laing G, et al. Fatal aplastic anemia after mesalazine. Lancet 1994;343:542.
14. Laidlaw ST, Reilly JT. Antilymphocyte globulin for mesalazine-associated aplastic anemia. Lancet 1994;343:981-982.
15. Daneshmend TK. Mesalazine-associated thrombocytopenia. Lancet 1991;337:1297-1298.
16. Penston J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol 1986;1:192-216.
17. Aymard JP, Aymard B, Netter P, et al. Hematological adverse effects of histamin H2-receptor antagonists. Med Toxicol Adverse Drug Exp 1988;3:430-448.
18. Fardy JM, Lloyd DA, Reynolds RP. Adverse effects with oral 5-aminosalicylic acid. J Clin Gastroenterol 1988;10:635-637.
19. Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to salfasalazine. Gastroenterology 1992;103:1925-1927.
20. Thuluvath PJ, Ninkovic M, Calam J, et al. Mesalazine induced interstitial nephritis. Gut 1994;35:1493-1496.
21. Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-amino salicylic acid. Nephron 1994;67:481-482.
22. Poldermans D, van Blankenstein M. Pancreatitis induced by disodium azodi-salicylate. Am J Gastroenterol 1988;83:578-580.
23. Fiorentini MT, Fracchia M, Galatola G, et al. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990;35: 1180-1182.
24. Agnholt J, Sorensen HT, Rasmussen SN, et al. Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 1989;1:1135.
25. Kristensen KS, Hoegholm A, Bohr L, et al. Fatal myocarditis associated with mesalazine. Lancet 1990;335:605.
26. Honeybourne D. Mesalazine toxicity. BMJ 1994;308:533-534.
27. Bitton A, Peppercorn MA, Hanrahan JP, et al. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996;91:1039-1040.
28. Woodward DK. Peripheral neuropathy and mesalazine. BMJ 1989;299:1224.
29. Das KM, Eastwood MA, McManus JPA, et al. Adverse reactions during salicylazo sulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289: 491-495.
30. Keiser M, Ekman E. Sulfasalazine-associated agranulocytosis in Sweden 1972-1987. Eur J Clin Pharmacol 1992;43:215-218.
31. Chiba M, Munakata A, Takahashi T, et al. Side effects of salicylazosulfapyridine in inflammatory bowel disease. In: Muto T (ed) Annual report of the Research Committee of Inflammatory Bowel Disease, The Ministry of Health and Welfare of Japan. (In Japanese with English abstract). Tokyo: Ministry of Health and Welfare of Japan, 1994;102-106.
32. Jick H, Wald Myers M, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15:176-181.
33. Committee on Safety of Medicine. Blood dyscrasias and mesalazine. Curr Probl Pharmacovigilance 1995;21:5-6.
34. Amos RS, Pullan T, Box DE, et al. Sulphasalazine for rheumatoid arthritis: Toxicity in 774 patients monitored for 1-11 years. BMJ 1986;293:420-423.